| Popis: |
BACKGROUND Sickle cell anemia or SCA is a homozygous condition of Sickle cell disease or SCD, in which patients presents with a chronic and progressive condition which is characterised by hemolytic anemia, recurrent vaso-occlusive events, along with complications like organ dysfunction. Hydroxyurea has emerged as a break-through in treatment of Sickle cell anemia. Currently it is the only FDA approved drug which has shown disease modifying results. OBJECTIVE To determine the clinical outcome and laboratory parameters in SCA patients of pediatric age group post-hydroxyurea therapy. METHODS A total of 30 patients who were diagnosed as Sickle cell anemia(SCA) patients in Sickle cell anemia OPD of Pediatric department were included in the study. RESULTS Hydroxyurea therapy is expected to increase HbF% levels and improve the clinical outcome and laboratory parameters in sickle cell anemia patients of pediatric age group. CONCLUSIONS Hydroxyurea use increases HbF%, decrease painful crises, blood transfusion, and days of hospitalisation. |
